What does north american pharmaceutical — non-cash charges mean?

Aggregated non-cash expenses, such as depreciation, amortization, and asset impairments, allocated to the North American pharmaceutical segment. These charges represent the consumption of long-lived assets and accounting adjustments that do not impact immediate cash flow.

McKesson (MCK) North American Pharmaceutical — Non-cash charges

Screener

Other segment segments

Prescription Technology Solutions

$40M—

Medical-Surgical Solutions

$0—

Oncology & Multispecialty

$0-100%

Similar metrics at other companies

GFFDiscontinued Operations — Non-cash charges

$20.67M-65.4%

ESABAmericas: — Non-cash charges

$7.92M—

MYPSplayAWARDS — Restructuring Reserve, Settled without Cash

$71K—

MYPSplayGAMES — Restructuring Reserve, Settled without Cash

$312K—

BCBoat — Restructuring Reserve, Settled without Cash

$275K+467%

BCCorporate — Restructuring Reserve, Settled without Cash

$0—

Other financials

Income statement

See full

Revenue$105.38B+7.7%

Gross profit$3.7B+12.4%

Operating income$1.3B+27.3%

Net income$614.0M-21.7%

EPS (diluted)$5.15-17.6%

Balance sheet

See full

Cash & equivalents$5.3B+95.9%

Total debt$13.0B+15.7%

Total equity-$4.2B-116%

Total assets$88.3B+8.6%

Cash flow

See full

Operating cash flow-$220.0M+76.0%

CapEx$112.0M+0.9%

Free cash flow-$332.0M+67.7%

Valuation

See full

Market cap$102.7B+16.8%

Enterprise value$110.42B+14.5%

P/E22.4×-5.4×

P/S0.3×0.0×

Profitability

See full

Gross margin3.6%+0.1pp

Operating margin1.6%+0.4pp

Net margin1.1%+0.3pp

FCF margin1.6%0.0pp

Returns & leverage

See full

Return on equity36%—

Debt / equity2×—

Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:RestructuringReserveSettledWithoutCash2.

The source filing: McKesson’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 5:29 PM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0000927653-26-000234

(In millions)	North American Pharmaceutical	Prescription Technology Solutions	Medical-Surgical Solutions	Corporate	Total
Balance, March 31, 2026 (1)	$18	$3	$10	$13	$44
Restructuring, impairment, and related charges, net	2	61	23	50	136
Non-cash charges	(1)	(40)	—	(6)	(47)
Cash payments	(3)	—	(16)	(40)	(59)
Balance, June 30, 2026 (2)	$16	$24	$17	$17	$74

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is McKesson's north american pharmaceutical — non-cash charges?: McKesson (MCK) reported north american pharmaceutical — non-cash charges of $1M in Q2 2026.
What does north american pharmaceutical — non-cash charges mean?: Aggregated non-cash expenses, such as depreciation, amortization, and asset impairments, allocated to the North American pharmaceutical segment. These charges represent the consumption of long-lived assets and accounting adjustments that do not impact immediate cash flow.